Open Orphan further contract renewal with top-3 global pharmaceutical client

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced a further contract renewal with a major top-3 global pharmaceutical client extending its consultancy services to end of December 2021. This follows on from the announcement made on 22 December 2020 regarding the same client and demonstrates the repeat business that Venn Life Sciences continues to win from its long-term clients.

The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing & Control consultancy services to this leading global pharmaceutical client for one of the client’s vaccine development programmes and follows the recently announced contract renewal for work on two of the client’s vaccine development programmes. This successful collaboration has been extended until end of December 2021.

Cathal Friel, Executive Chairman of Open Orphan, said: “We are delighted to enter 2021 with another contract signed by the Venn team in Breda with this top-3 global pharmaceutical client. Venn have been providing CMC support to this top tier company since 2012 and are pleased to be continuing to work with this client in their vaccine development programme.

“This contract demonstrates the depth of vaccine development knowledge across the Company and, in addition to being the world leader in vaccine and antiviral testing using human challenge clinical trials, reinforces our position as the go-to clinical research organisation for many other services required by both large pharma and vaccine developers at all stages of development.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Monkeypox: The Lowdown

An ongoing outbreak of monkeypox was confirmed on 6 May 2022, beginning with a British resident who, after travelling to Nigeria, presented symptoms consistent with monkeypox on 29 April 2022. The resident returned to the United

Open Orphan Plc

Open Orphan’s hVIVO signs a £14.7m influenza contract

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan plc, has signed

Open Orphan Plc

How to stop the spread of germs

Flu season often wreaks havoc on workplaces, schools and communal living areas. It’s all too easy for germs to spread across surfaces and between people, swiftly infecting everyone within reach. It’s important to do what you

Open Orphan Plc

Open Orphan due diligence completed by Liberum Capital

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has today announced that further to the appointment of Liberum

Open Orphan Plc

Can elderberries help to fight the flu?

Elderberries have long been in the limelight when it comes to their health-boosting properties. In fact, Healthline declared them to be “one of the most commonly used medicinal plants in the world”. Now, researchers think they may have

Open Orphan Plc

Open Orphan to publish full year results on 7 June 2022

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it will release its full year results for

Open Orphan Plc

Open Orphan’s hVIVO wins a £7.3m influenza human challenge study

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has signed

Open Orphan Plc

The History of Flu

Flu & Influenza The history of the flu dates to as far as humankind. Familiar symptoms of the flu were first recorded around 400BC by Hippocrates, a Turkish seasonal winter to spring respiratory ailment that resulted

Open Orphan Plc

The lowdown on hay fever

Allergic rhinitis or, as it is commonly known, hay fever, is a reaction to allergens in the air. Most commonly this is a reaction to the pollen count, but can also be to dust, mould or

Open Orphan Plc

What is a Human Challenge Study?

During a human challenge study, a small number of healthy volunteers will receive a vaccine or drug which will be used to fight viruses. Volunteers are quarantined in our bespoke facilities in Whitechapel. We expose our